商务合作
动脉网APP
可切换为仅中文
Mumbai: Strides Pharma International AG, a step‑down subsidiary of Bengaluru-based
孟买:班加罗尔的间接子公司Strides Pharma International AG,
Strides Pharma Science
斯特莱兹制药科学
, has entered into definitive agreements with
,已与...签订了最终协议
Sandoz AG
山德士股份公司
, Switzerland and its group entities for acquisition and in‑licensing of a portfolio of
,瑞士及其集团实体收购和许可引进了以下产品组合
branded generic products
品牌仿制药
across sub‑Saharan Africa.
横跨撒哈拉以南非洲。
The initial consideration for the transaction is $12 million, payable at closing and is expected to be funded through internal accruals, Strides said in a statement. The transaction is expected to be EPS‑accretive, supported by profitable branded sales, synergy realisation, and improved operating leverage..
Strides 在一份声明中表示,本次交易的初始对价为 1200 万美元,将在交割时支付,并预计通过内部积累提供资金。本次交易预计将增厚每股收益 (EPS),得益于盈利的品牌销售、协同效应的实现以及运营杠杆的提升。
Also Read:
另请阅读:
Mankind Pharma targets early Semaglutide launch
人类制药公司目标提早推出司美鲁肽
The transaction is expected to close by the end of Q2 FY27 (quarter ending September 2026), subject to customary closing conditions, including regulatory and antitrust approvals in applicable jurisdictions.
该交易预计将在2027财年第二季度末(即2026年9月结束的季度)完成,但需满足惯例的交割条件,包括在适用司法管辖区获得监管和反垄断批准。
“This acquisition represents a significant milestone for our ‘in Africa for Africa’ strategy,” said Aditya Kumar, Executive Director, Business Development, Strides. “Africa is one of the fastest-growing geographies for us, and this transaction more than doubles our presence in the region, giving us the size and scale to accelerate our momentum, deepen market penetration, and further consolidate our leadership across key therapeutic areas,” he added.
“这次收购代表了我们‘立足非洲,服务非洲’战略的重要里程碑,”Strides业务发展执行董事阿迪亚·库马尔表示。“非洲是我们增长最快的地区之一,此次交易使我们在该地区的存在扩大了一倍以上,为我们加速发展、深化市场渗透,并进一步巩固我们在关键治疗领域的领导地位提供了规模和实力,”他补充道。
.
。
Live Events
现场活动
The agreement spans four key markets including Western Sahara (covering 10 countries), Ghana, Nigeria, and Kenya. The branded generics portfolio of Sandoz, as a part of this deal, includes multiple brands across anti‑infective, cardiovascular, and dermatology therapeutic segments. Several of these products individually deliver annual sales exceeding $1 million..
该协议涵盖四个关键市场,包括西撒哈拉(覆盖10个国家)、加纳、尼日利亚和肯尼亚。作为此协议的一部分,山德士的品牌仿制药组合包括抗感染、心血管和皮肤病治疗领域的多个品牌。其中几种产品单个的年销售额超过100万美元。
The transaction includes a portfolio comprising products that are being fully acquired by Strides, as well as select products that Strides will continue to market on behalf of Sandoz.
该交易包括一个产品组合,其中一些产品将由Strides完全收购,另外还有一些产品将由Strides继续代表山德士进行销售。
Also Read:
另请阅读:
India pharma production hit by propane shortage; vitamin, hormone supply at risk
印度制药生产因丙烷短缺受影响;维生素、激素供应面临风险
To ensure the uninterrupted availability of these critical brands, Strides will also enter into a manufacturing and supply agreement with Sandoz for their continued production and supply, the statement noted.
声明指出,为了确保这些关键品牌的持续供应,Strides 还将与 Sandoz 达成制造和供应协议,以继续生产和供应。
With the combined strength of Strides’ existing business and the branded portfolio being acquired from Sandoz, Strides is expected to become one of the top five pharmaceutical companies in the sub‑Saharan Africa region by sales and among the top two players in the representable market.
通过斯特莱德现有业务与从山德士收购的品牌组合的综合优势,预计斯特莱德将成为撒哈拉以南非洲地区销售额排名前五的制药公司,以及在可代表市场中的前两大竞争者之一。
“This investment is aligned with our long‑term strategy, under which ex‑US markets are expected to evolve to mirror the scale of our US business within a couple of years. The combined portfolio strengthens our market position by enhancing our overall visibility in retail pharmacy and substantially increasing the depth and breadth of our offerings across the hospital network,” said Kumar..
“这项投资与我们的长期战略一致,根据该战略,预计美国以外市场将在几年内发展到与我们美国业务规模相当的水平。合并后的组合通过增强我们在零售药房的整体知名度,并大幅增加我们在医院网络中的产品深度和广度,巩固了我们的市场地位,”库马尔说。
Add
添加
as a Reliable and Trusted News Source
作为一个可靠和值得信赖的新闻来源
Add Now!
立即添加!
(You can now subscribe to our
(你现在可以订阅我们的
Economic Times WhatsApp channel
经济时报WhatsApp频道
)
)
(You can now subscribe to our
(您现在可以订阅我们的
Economic Times WhatsApp channel
经济时报WhatsApp频道
)
)